317 related articles for article (PubMed ID: 16467855)
1. Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer.
Mesters JR; Barinka C; Li W; Tsukamoto T; Majer P; Slusher BS; Konvalinka J; Hilgenfeld R
EMBO J; 2006 Mar; 25(6):1375-84. PubMed ID: 16467855
[TBL] [Abstract][Full Text] [Related]
2. Structural basis of interactions between human glutamate carboxypeptidase II and its substrate analogs.
Barinka C; Hlouchova K; Rovenska M; Majer P; Dauter M; Hin N; Ko YS; Tsukamoto T; Slusher BS; Konvalinka J; Lubkowski J
J Mol Biol; 2008 Mar; 376(5):1438-50. PubMed ID: 18234225
[TBL] [Abstract][Full Text] [Related]
3. Reaction mechanism of glutamate carboxypeptidase II revealed by mutagenesis, X-ray crystallography, and computational methods.
Klusák V; Barinka C; Plechanovová A; Mlcochová P; Konvalinka J; Rulísek L; Lubkowski J
Biochemistry; 2009 May; 48(19):4126-38. PubMed ID: 19301871
[TBL] [Abstract][Full Text] [Related]
4. Identification of the N-glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activity.
Barinka C; Sácha P; Sklenár J; Man P; Bezouska K; Slusher BS; Konvalinka J
Protein Sci; 2004 Jun; 13(6):1627-35. PubMed ID: 15152093
[TBL] [Abstract][Full Text] [Related]
5. Design of highly potent urea-based, exosite-binding inhibitors selective for glutamate carboxypeptidase II.
Tykvart J; Schimer J; Jančařík A; Bařinková J; Navrátil V; Starková J; Šrámková K; Konvalinka J; Majer P; Šácha P
J Med Chem; 2015 May; 58(10):4357-63. PubMed ID: 25923815
[TBL] [Abstract][Full Text] [Related]
6. Structure-activity relationships of glutamate carboxypeptidase II (GCPII) inhibitors.
Ferraris DV; Shukla K; Tsukamoto T
Curr Med Chem; 2012; 19(9):1282-94. PubMed ID: 22304717
[TBL] [Abstract][Full Text] [Related]
7. Molecular modeling of the interactions of glutamate carboxypeptidase II with its potent NAAG-based inhibitors.
Rong SB; Zhang J; Neale JH; Wroblewski JT; Wang S; Kozikowski AP
J Med Chem; 2002 Sep; 45(19):4140-52. PubMed ID: 12213057
[TBL] [Abstract][Full Text] [Related]
8. Human glutamate carboxypeptidase II inhibition: structures of GCPII in complex with two potent inhibitors, quisqualate and 2-PMPA.
Mesters JR; Henning K; Hilgenfeld R
Acta Crystallogr D Biol Crystallogr; 2007 Apr; 63(Pt 4):508-13. PubMed ID: 17372356
[TBL] [Abstract][Full Text] [Related]
9. S1 pocket of glutamate carboxypeptidase II: a new binding site for amyloid-β degradation.
Lee SK; Kim H; Cheong YH; Kim MJ; Jo SA; Youn HS; Park SI
Biochem Biophys Res Commun; 2013 Sep; 438(4):765-71. PubMed ID: 23891752
[TBL] [Abstract][Full Text] [Related]
10. Structural insight into the evolutionary and pharmacologic homology of glutamate carboxypeptidases II and III.
Hlouchova K; Barinka C; Konvalinka J; Lubkowski J
FEBS J; 2009 Aug; 276(16):4448-62. PubMed ID: 19678840
[TBL] [Abstract][Full Text] [Related]
11. Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer.
Bařinka C; Rojas C; Slusher B; Pomper M
Curr Med Chem; 2012; 19(6):856-70. PubMed ID: 22214450
[TBL] [Abstract][Full Text] [Related]
12. Structural insight into the pharmacophore pocket of human glutamate carboxypeptidase II.
Barinka C; Rovenská M; Mlcochová P; Hlouchová K; Plechanovová A; Majer P; Tsukamoto T; Slusher BS; Konvalinka J; Lubkowski J
J Med Chem; 2007 Jul; 50(14):3267-73. PubMed ID: 17567119
[TBL] [Abstract][Full Text] [Related]
13. Mapping of the active site of glutamate carboxypeptidase II by site-directed mutagenesis.
Mlcochová P; Plechanovová A; Barinka C; Mahadevan D; Saldanha JW; Rulísek L; Konvalinka J
FEBS J; 2007 Sep; 274(18):4731-41. PubMed ID: 17714508
[TBL] [Abstract][Full Text] [Related]
14. Structural characterization of P1'-diversified urea-based inhibitors of glutamate carboxypeptidase II.
Pavlicek J; Ptacek J; Cerny J; Byun Y; Skultetyova L; Pomper MG; Lubkowski J; Barinka C
Bioorg Med Chem Lett; 2014 May; 24(10):2340-5. PubMed ID: 24731280
[TBL] [Abstract][Full Text] [Related]
15. Glutamate carboxypeptidase II: an overview of structural studies and their importance for structure-based drug design and deciphering the reaction mechanism of the enzyme.
Pavlícek J; Ptácek J; Barinka C
Curr Med Chem; 2012; 19(9):1300-9. PubMed ID: 22304708
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase II: efficacy as analgesic agents.
Kozikowski AP; Zhang J; Nan F; Petukhov PA; Grajkowska E; Wroblewski JT; Yamamoto T; Bzdega T; Wroblewska B; Neale JH
J Med Chem; 2004 Mar; 47(7):1729-38. PubMed ID: 15027864
[TBL] [Abstract][Full Text] [Related]
17. In silico approaches to identify the potential inhibitors of glutamate carboxypeptidase II (GCPII) for neuroprotection.
Naushad SM; Janaki Ramaiah M; Stanley BA; Prasanna Lakshmi S; Vishnu Priya J; Hussain T; Alrokayan SA; Kutala VK
J Theor Biol; 2016 Oct; 406():137-42. PubMed ID: 27430729
[TBL] [Abstract][Full Text] [Related]
18. Detection and quantitation of glutamate carboxypeptidase II in human blood.
Knedlík T; Navrátil V; Vik V; Pacík D; Šácha P; Konvalinka J
Prostate; 2014 May; 74(7):768-80. PubMed ID: 24647901
[TBL] [Abstract][Full Text] [Related]
19. Expression of glutamate carboxypeptidase II in human brain.
Sácha P; Zámecník J; Barinka C; Hlouchová K; Vícha A; Mlcochová P; Hilgert I; Eckschlager T; Konvalinka J
Neuroscience; 2007 Feb; 144(4):1361-72. PubMed ID: 17150306
[TBL] [Abstract][Full Text] [Related]
20. Rationally designed sulfamides as glutamate carboxypeptidase II inhibitors.
Choy CJ; Fulton MD; Davis AL; Hopkins M; Choi JK; Anderson MO; Berkman CE
Chem Biol Drug Des; 2013 Nov; 82(5):612-9. PubMed ID: 23773397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
